Why This Guide Exists
If you’re reading this, you or someone you care about probably needs a GLP-1 medication and is trying to figure out how to actually get one. That’s a reasonable and often urgent problem. The landscape is genuinely complicated: there are multiple access tiers with different legal status, cost structures, quality profiles, and risk considerations. What’s right for one person may not be right for another.
This guide presents each option honestly, without recommending any specific path. There’s no affiliate relationship with any manufacturer, pharmacy, telehealth platform, or supplier. The goal is to give you the clearest possible map of what exists and what distinguishes each tier. What you do with it is your decision, and your prescriber’s.
All Four Tiers at a Glance
| Tier | What it is | Approx. Monthly Cost | Rx Required? | FDA-Approved Product? | Medical Oversight? |
|---|---|---|---|---|---|
| Tier 1 | Brand-name without insurance, using manufacturer savings | ~$25–$600/mo (savings program dependent) | Yes | Yes | Yes (through prescriber) |
| Tier 2 | Insurance-covered brand-name | $0–$100/mo with coverage | Yes | Yes | Yes (through prescriber) |
| Tier 3 | Telehealth + compounded GLP-1 (503A/503B pharmacies) | ~$150–$500/mo | Yes (included in program) | No (compounded) | Yes (included in program) |
| Tier 4 | Research peptide GLP-1 compounds | ~$30–$150/mo (use-dependent) | No | No | No (self-managed) |
What It Is
This tier covers the brand-name GLP-1 receptor agonists approved by the FDA for weight management or type 2 diabetes: Ozempic and Wegovy (semaglutide, manufactured by Novo Nordisk) and Mounjaro and Zepbound (tirzepatide, manufactured by Eli Lilly). These are finished drug products manufactured under pharmaceutical GMP conditions, dispensed by licensed pharmacies, and requiring a prescription from a licensed prescriber.
Without any discounts, the retail list price is approximately $900–$1,000/month for Ozempic and $1,200–$1,400/month for Wegovy. Mounjaro and Zepbound run similarly, $900–$1,200/month depending on dose. Most people do not pay these prices.
Manufacturer Savings Programs
Both Novo Nordisk and Eli Lilly offer savings programs that can substantially reduce cost for commercially insured and uninsured patients who meet eligibility requirements:
- Savings cards (NovoCare, Lilly’s savings program): For commercially insured patients, savings cards can reduce copays to as low as $25–$99/month. These do not apply to Medicare or Medicaid. Eligibility and benefit maximums vary and change periodically.
- Patient Assistance Programs (PAP): For uninsured or underinsured patients meeting income criteria (generally up to 400–600% of federal poverty level), these programs can provide the medication for free. Novo Nordisk’s PAP covers Ozempic and Wegovy; Lilly Cares Foundation covers Mounjaro and Zepbound. These require an application and income verification.
- Savings card stacking: Commercially insured patients who also qualify for a manufacturer savings card can sometimes reduce net out-of-pocket to close to $0/month. This is the best possible scenario for cost.
- Highest regulatory assurance of any tier
- Pharmaceutical GMP manufacturing, FDA oversight
- Established safety and efficacy data from clinical trials
- Standardized, prefilled dosing device (pen injector)
- Patient assistance can reduce cost to $0 for qualifying patients
- Broad prescriber familiarity with the product
- List price of $900–$1,400/month is inaccessible for most without coverage
- Savings cards exclude Medicare and Medicaid patients
- PAP application process takes time; not instant access
- Intermittent supply constraints in some markets
- Without a savings pathway, this is the most expensive tier
Patients who qualify for manufacturer patient assistance (uninsured, income-qualifying), commercially insured patients who qualify for savings card programs, and patients with complex health histories where the additional regulatory assurance of a pharmaceutical-grade product with documented manufacturing standards is particularly important.
What It Is
This is the same product as Tier 1 — brand-name Ozempic, Wegovy, Mounjaro, or Zepbound — but with insurance covering the majority of the cost. The net monthly out-of-pocket for a well-covered patient using savings card stacking can approach $0. For most insured patients without stacking, copays of $25–$100/month are common with good commercial coverage.
This is the optimal scenario: highest-quality product at the lowest possible cost. Getting here, however, typically requires navigating prior authorization, and denials are common.
Getting Coverage: Prior Authorization
Most commercial insurance plans require prior authorization before covering a GLP-1. Approval typically depends on meeting one or more clinical criteria:
- BMI threshold: often ≥30 (or ≥27 with a documented comorbidity such as type 2 diabetes, hypertension, or sleep apnea)
- Documentation by a treating physician that the medication is medically necessary
- Step therapy: some plans require documented trial of cheaper alternatives first
- Specific ICD-10 diagnosis codes in the prescriber’s prior auth request
Importantly: GLP-1s for weight management are generally not covered by Medicare Part D. The Inflation Reduction Act and subsequent regulatory action are evolving this, but as of May 2026, coverage for obesity indication under Medicare Part D remains limited. Type 2 diabetes indication (Ozempic, Mounjaro) may be covered under Medicare Part D; verify with your specific plan.
When You Get Denied
Initial denials are common and are frequently worth appealing. The appeal process involves submitting a formal request for reconsideration with supporting clinical documentation. Strategies that improve appeal success rates include:
- Requesting the specific clinical criteria the insurer applied
- Having your prescriber document comorbidities and clinical necessity in detail
- Peer-to-peer review (your prescriber speaks directly with the insurance plan’s medical director)
- External appeal to an independent review organization if internal appeal fails
- Lowest net cost for those who can access it
- Highest regulatory assurance of any product tier
- Prescriber relationship built into the access pathway
- Savings card stacking can reduce copay to near $0
- Familiar to pharmacists and prescribers alike
- Prior auth burden; denials are common
- Step therapy requirements on many plans
- Medicare Part D generally does not cover weight management indication
- Employer self-insured plans vary widely in coverage
- Savings cards unavailable to Medicare/Medicaid patients
- Prior auth renewal may be required periodically
Patients with commercial insurance who meet clinical criteria for prior authorization, or who have had a denial and are willing to pursue the appeals process. If you have commercial insurance and a qualifying diagnosis, exhausting Tier 2 options before moving to other tiers generally makes sense given the cost differential.
What Compounding Is — and What It Isn’t
Compounding is the practice of a licensed pharmacy preparing a customized medication for a specific patient, using active pharmaceutical ingredients (APIs). It is a long-established practice in American pharmacy, used to create products not commercially available in the needed form, dose, or formulation.
There are two types of compounding pharmacies relevant here:
- 503A pharmacies: Traditional compounding pharmacies that prepare products on a patient-specific prescription basis. Regulated primarily by state pharmacy boards, not the FDA.
- 503B outsourcing facilities: Larger facilities that can compound in bulk and are subject to more rigorous FDA oversight, including cGMP requirements and FDA inspections.
Compounded products are not FDA-approved finished drug products. The FDA has not reviewed them for safety, efficacy, or manufacturing consistency in the same way it reviews Ozempic or Wegovy. They are legally distinct from the brand-name drugs, even when they contain the same active pharmaceutical ingredient.
The Legal Basis — and the Current Contested Landscape
Compounding of a commercially available drug is generally not permitted — with an important exception: when the FDA places a drug on its drug shortage list, compounding pharmacies may compound that drug. Semaglutide was on the FDA shortage list for an extended period, which opened the door to widespread compounded semaglutide production by 503A and 503B pharmacies.
How Telehealth Programs Work
Platforms such as Hims & Hers, Ro, Henry Meds, and Eden Health (among others) operate a vertically integrated model: a telehealth prescriber evaluates your health history and writes a prescription; a licensed compounding pharmacy (their partner pharmacy) fills and ships the medication directly to you. You pay a monthly program fee that typically covers the consultation, prescription, and medication.
Program costs range approximately $150–$500/month depending on the drug (semaglutide vs. tirzepatide), dose level, and platform. Prices vary meaningfully across platforms for essentially the same product. Comparison shopping is worthwhile.
- Which specific pharmacy fills my prescription? Is it 503A or 503B?
- Can I obtain a Certificate of Analysis (CoA) for my lot?
- What is the base active ingredient? Is it semaglutide base, semaglutide sodium, or semaglutide acetate? (Bioequivalence data differs.)
- What is your current regulatory status in my state?
- How is dose titration managed? Is there ongoing clinical oversight?
- Medically supervised — a licensed prescriber is involved
- Pharmacy-dispensed, not self-sourced
- Significantly lower cost than brand-name without insurance
- Includes ongoing clinical oversight in most programs
- Access does not depend on insurance approval
- Not an FDA-approved finished drug product
- Most programs ended June 2026 — FDA shortage resolutions closed the mass-market compounding window
- Quality varies by pharmacy; no standardization equivalent to brand-name
- Not pharmacokinetically interchangeable with brand-name in all respects
- CoA availability and testing depth varies by platform
- Platform prices vary by $100–$200/month for the same medication
This tier is largely unavailable as of June 2026. FDA shortage resolutions for both semaglutide and tirzepatide have closed the compounding window for mass-market programs. Patients who relied on this path are now navigating the transition. Narrow 503A patient-specific prescriptions may still be available in some states for documented medical necessity — confirm with your prescriber. If your program is ending, see: Your Compounded GLP-1 Program Is Ending: What to Do Now →
What Research Peptides Are
Research peptides are peptide compounds sold by domestic US suppliers under a “for laboratory research use only — not for human consumption” designation. This means the product is not being sold as a drug, is not dispensed by a licensed pharmacist, and has not been reviewed or approved by the FDA as a pharmaceutical product. The manufacturer is not subject to pharmaceutical GMP requirements.
Research peptide suppliers sell semaglutide, tirzepatide, and other GLP-1 receptor agonists (including retatrutide and others not available through any prescription channel) in lyophilized powder form, typically by the milligram. The buyer is responsible for sourcing bacteriostatic water, sterile reconstitution, dosing calculation, and administration.
The Legal Designation — What It Means in Practice
The “research use only” designation is a legal framework that positions the product outside the drug regulatory framework. Buying a research peptide for personal use is not, in itself, a criminal act for consumers in most circumstances. However, the product has no legal status as a therapeutic drug, and using it for personal therapeutic purposes occupies a legally ambiguous position. The supplier’s liability is limited by the “not for human consumption” label.
Research peptide costs are dramatically lower than other tiers. At approximately $10–$20/mg for semaglutide and $14–$28/mg for tirzepatide (prices vary by supplier and market conditions), a month’s supply at therapeutic doses can run $30–$150 depending on the drug and dose.
Who Uses This Tier — and Why
The population using research peptide GLP-1s is varied. Some have genuinely exhausted every other option and cannot afford Tiers 1–3. Some are specifically seeking compounds not available through prescription channels — retatrutide being the most prominent example. Some are researchers, bodybuilding or performance communities, or people who prefer to self-manage their protocols. The reasons are diverse and often reflect the failure of the broader system to provide affordable access through legitimate channels.
This is worth acknowledging plainly: when a medication costs $900–$1,400/month on the legitimate market and $30–$150 through research peptide suppliers, the decision people make is understandable even when it involves real risk.
The Risks — Which Are Real, Not Theoretical
The absence of pharmaceutical manufacturing oversight creates risks that are genuine and documented through community testing campaigns:
- Identity failures: Receiving a different compound than labeled. Community-conducted independent testing campaigns have documented this at specific vendors. There is no systematic surveillance across the broader market.
- Dosing errors: Unlike prefilled pen injectors, research peptides require manual reconstitution and dosing calculation. Errors in concentration math, particularly with underfilled vials, can result in significant dose variation.
- Endotoxin contamination: Bacterial endotoxins (lipopolysaccharides) are a known risk in products manufactured outside sterile pharmaceutical conditions. Mild reactions — fever, chills, flu-like symptoms after injection — are commonly reported in the research peptide community and are consistent with endotoxin exposure. Severe reactions are possible with high endotoxin loads. Endotoxins survive lyophilization; bacteriostatic water does not neutralize them.
- Synthesis impurities: Peptide synthesis can produce byproducts that a standard HPLC purity test may not fully characterize. What a CoA confirms is that the compound passes a purity threshold on the specific sample tested; it does not confirm absence of all biologically relevant impurities.
Reducing Risk Within This Tier
For those who choose this tier with full awareness of what it involves, the risk mitigation approaches most supported by community experience include:
- Third-party independent lab testing (mass spectrometry identity confirmation, endotoxin testing) of your specific lot before use
- Prioritizing suppliers with long-standing community track records and publicly documented testing histories
- Sterile reconstitution technique (bacteriostatic water, alcohol swabs, proper storage)
- Starting at a low dose and titrating carefully, with heightened attention to atypical reactions
- Knowing what to do if you have an unexpected reaction
- Dramatically lower cost than any other tier
- Access to compounds not available by prescription (e.g., retatrutide)
- No insurance or prior authorization required
- No telehealth program enrollment required
- No FDA oversight of manufacturing or product quality
- No prescriber supervision or pharmacist dispensing
- Identity failures, dosing errors, and endotoxin contamination are documented risks
- Legal designation is “not for human consumption”
- Requires manual reconstitution and dosing calculation
- No standardized dosing device; higher potential for user error
- Requires the most buyer diligence of any tier
People who have worked through the options at higher tiers and determined they are not accessible — or who are specifically seeking compounds not available by prescription — and who are proceeding with full awareness of the legal designation, quality uncertainties, and practical risks. This tier rewards careful supplier evaluation, independent testing, and protocol discipline. It is not appropriate for people with complex comorbidities who need active clinical management.
→ Related: Health Canada's Generic Semaglutide Approval: Cross-Border Costs and US Importation Law — an emerging option tier worth understanding: what Canada's generic approval means for cost comparison, and what US law currently says about importation.
Decision Framework
The following is a set of questions to work through, not a flowchart that leads to a product recommendation. Your situation is specific; these questions are designed to help you identify which tiers are actually accessible to you.
A Note on Medical Supervision
GLP-1 receptor agonists are potent drugs. They work — that’s why people want them — and they have real side effects and real contraindications. Regardless of which tier you use, a few things are worth understanding:
- Contraindications that apply to all GLP-1 receptor agonists: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) are contraindications to GLP-1 use. History of pancreatitis requires careful evaluation. These are reasons the prescription framework exists, and they don’t disappear because someone is using a research peptide.
- Dose titration matters: The start-low-and-titrate approach standard in clinical practice exists because GI side effects are common and dose-dependent. Rushing titration increases the likelihood and severity of nausea, vomiting, and other effects.
- Drug interactions: GLP-1s slow gastric emptying, which affects absorption of oral medications. If you take oral medications with narrow therapeutic windows, this is a meaningful consideration.
- Monitoring: Prescribers following patients on GLP-1s typically monitor for kidney function, thyroid changes, and other parameters. The monitoring infrastructure is a real benefit of supervised tiers.
This section exists to inform, not to shame anyone for the choices the system forces on them. The fact that a medication requires close monitoring is a legitimate reason it sits behind a prescription requirement — it’s also true that millions of people have used GLP-1s across multiple tiers without access to the full supervised infrastructure. Understanding what the monitoring is for helps you be more alert to what matters, regardless of which tier you choose.
Frequently Asked Questions
The cheapest legal path depends on your situation. For uninsured patients who meet income criteria (generally up to 400–600% of federal poverty level), manufacturer patient assistance programs — Novo Nordisk’s PAP for semaglutide products, Lilly Cares for tirzepatide products — can provide brand-name medication for free. Telehealth programs using compounded GLP-1 medications were previously a lower-cost option at approximately $150–$500/month, but most of these programs have ended as of June 2026 following FDA shortage resolutions. Generic liraglutide (Saxenda/Victoza) remains available at substantially lower cost than semaglutide or tirzepatide brand products and may be an option for some patients. See our transition guide for the current ranked options.
Brand-name GLP-1 products (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved finished drug products manufactured under pharmaceutical GMP conditions by Novo Nordisk and Eli Lilly. Compounded GLP-1 products are prepared by licensed compounding pharmacies using the active pharmaceutical ingredient but are not FDA-approved finished drug products — they have not undergone the same pre-market review for safety, efficacy, and manufacturing consistency. Quality varies by pharmacy. The FDA does not consider compounded and brand-name GLP-1 products interchangeable.
Research peptides sold domestically are typically sold under a “for laboratory research use only — not for human consumption” designation. Purchasing such a product for personal research use is not, by itself, a criminal act for consumers in most cases. However, the product is not legally authorized for therapeutic human use without a prescription, and its manufacture is not subject to pharmaceutical GMP requirements. The legal status is nuanced and context-dependent rather than a simple yes or no — research peptides occupy a legally ambiguous space that is distinct from both clearly legal and clearly illegal.
There is no universal answer — the right tier depends on your insurance status, income, health history, risk tolerance, and which options are currently available in your state. The general approach: exhaust insurance coverage options (Tier 2) first if you have commercial insurance; check manufacturer patient assistance eligibility (Tier 1 pathway) before spending anything if you’re uninsured; note that Tier 3 mass-market compounding programs have largely ended as of June 2026 — narrow 503A patient-specific prescriptions may still be available in some states; consider research peptides (Tier 4) only with full awareness of what that tier involves. The decision framework section of this guide walks through the key questions in sequence.
In terms of medical oversight structure, telehealth programs involve a licensed prescriber and a licensed pharmacy — which is comparable to a traditional prescriber visit for purposes of the prescription and dispensing pathway. The meaningful difference is the product itself: compounded GLP-1 products are not FDA-approved finished drug products and vary in quality by pharmacy, whereas brand-name products from Novo Nordisk and Eli Lilly carry full pharmaceutical manufacturing oversight. Asking which pharmacy fills your prescription, whether it is 503A or 503B, and whether you can obtain a Certificate of Analysis is reasonable due diligence. Telehealth compounded programs are meaningfully different from research peptides, which involve no prescriber, no pharmacist, and no regulatory manufacturing requirements.